Patents by Inventor Marielle Chiron-Blondel

Marielle Chiron-Blondel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20230416395
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: April 14, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Anti-CD38 antibodies and formulations
    Patent number: 11655302
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 23, 2023
    Assignee: SANOFI
    Inventors: Marielle Chiron Blondel, Cendrine Lemoine, Angela Virone-Oddos, Béatrice Cameron, Jacques Dumas, Alain Fournier, Jonathan Kingsbury, Brian Murray, Nathan Ostberg, Sanket Patke, Zichuan Zhang
  • Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
    Patent number: 11208461
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 28, 2021
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
    Publication number: 20210293821
    Abstract: The present invention concerns the use of VCAM-1, ICAM-1 and/or PlGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 23, 2021
    Inventors: Jennifer DREYMANN, Caroline PACCARD, Marielle CHIRON-BLONDEL
  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER
    Publication number: 20200157181
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: October 24, 2019
    Publication date: May 21, 2020
    Inventors: Marielle CHIRON-BLONDEL, Diether LAMBRECHTS, Emmanuelle MAGHERINI, Vincent THUILLIER
  • IL-8 level based method of predicting the outcome of colon cancer treatment
    Patent number: 10501523
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: December 10, 2019
    Assignee: SANOFI
    Inventors: Marielle Chiron-Blondel, Diether Lambrechts, Emmanuelle Magherini, Vincent Thuillier
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20190275147
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: February 11, 2019
    Publication date: September 12, 2019
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
    Publication number: 20180113134
    Abstract: The present invention concerns the use of VCAM-1, ICAM-1 and/or PIGF as biomarkers for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: January 25, 2017
    Publication date: April 26, 2018
    Inventors: Jennifer DREYMANN, Caroline PACCARD, Marielle CHIRON-BLONDEL
  • METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER
    Publication number: 20170121387
    Abstract: The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventors: Marielle CHIRON-BLONDEL, Diether LAMBRECHTS, Emmanuelle MAGHERINI, Vincent THUILLIER
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20140127202
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: Aventis Pharma S.A.
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS
    Publication number: 20130330341
    Abstract: The invention relates to the treatment and the diagnosis of a group of patients bearing specific alleles of single nucleotide polymorphisms in the promoter region of the VEGFA gene. These patients are more responsive to Aflibercept and more likely to be efficiently treated by anti-VEGF therapy.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 12, 2013
    Applicant: SANOFI
    Inventors: Marielle Chiron Blondel, Emmanuelle Cousin, Jean-Francois Deleuze, Jennifer Dreymann, Sandrine Mace
  • Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
    Patent number: 8388963
    Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 5, 2013
    Assignees: Aventis Pharma SA, Regeneron Pharmaceuticals Inc
    Inventors: Patricia Vrignaud, Marielle Chiron-Blondel, Marie-Christine Bissery, Eric Furfine, Jocelyn Holash, Jesse M. Cedarbaum
  • Combination Comprising Combretastatin and Anticancer Agents
    Publication number: 20110054035
    Abstract: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 3, 2011
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marie-Christine BISSERY, Patricia VRIGNAUD, Marielle CHIRON-BLONDEL, Brigitte DEMERS
  • Combination comprising combretastatin and anticancer agents
    Patent number: 7851443
    Abstract: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: December 14, 2010
    Assignee: Aventis Pharma SA
    Inventors: Marie-Christine Bissery, Patricia Vrignaud, Marielle Chiron-Blondel, Brigitte Demers
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20100160233
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: January 4, 2010
    Publication date: June 24, 2010
    Applicant: Aventis Pharma S.A.
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF
    Publication number: 20090285841
    Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
    Type: Application
    Filed: July 24, 2009
    Publication date: November 19, 2009
    Applicants: AVENTIS PHARMA SA, REGENERON PHARMACEUTICALS INC.
    Inventors: Patricia VRIGNAUD, Marielle CHIRON-BLONDEL, Marie-Christine BISSERY, Eric FURFINE, Jocelyn HOLASH, Jesse M. CEDARBAUM
  • Combination Comprising Combretastatin and Anticancer Agents
    Publication number: 20090023656
    Abstract: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.
    Type: Application
    Filed: June 19, 2008
    Publication date: January 22, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Marie-Christine BISSERY, Patricia VRIGNAUD, Marielle CHIRON-BLONDEL, Brigitte DEMERS
  • Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
    Publication number: 20060178305
    Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.
    Type: Application
    Filed: December 2, 2005
    Publication date: August 10, 2006
    Applicant: Aventis Pharma S.A.
    Inventors: Patricia Vrignaud, Marielle Chiron-Blondel, Marie-Christine Bissery, Eric Furfine, Jocelyn Holash, Jesse Cedarbaum